Markets took notice of Pfizer/BioNTech's COVID-19 vaccine, that proved more than 90% effective among early stage trial participants. That fueled a market rally that boosted some of the sectors hardest hit by the coronavirus. Stephen Innes, Chief Market Strategist for the APAC region at AxiCorp, spoke to us on Prime Time about how big a deal this is, and whether this may trigger a rotation into battered value stocks, and emerging markets.

<p>Markets took notice of Pfizer/BioNTech's COVID-19 vaccine, that proved more than 90% effective among early stage trial participants. That fueled a market rally that boosted some of the sectors hardest hit by the coronavirus. Stephen Innes, Chief Market Strategist for the APAC region at AxiCorp, spoke to us on Prime Time about how big a deal this is, and whether this may trigger a rotation into battered value stocks, and emerging markets.</p>

Advertisement